GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...

Co-administration of the RSV and shingles adjuvanted vaccines was well tolerated, with acceptable reactogenicity and safety ...

Shingrix is approved to prevent shingles (herpes zoster) in adults aged 50 and older ... Also Read: GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

The incidence of herpes zoster was 5.4 cases vs ... shorter in the vaccinated group (21 days vs. 24 days). Most vaccine adverse effects were mild, including varicella-like rashes at the injection ...

A man in Saudi Arabia diagnosed with shingles suffered a rare and potentially life-threatening infection that ate away the ...

GSK plc (LSE/NYSE: GSK) is partnering with Brooke Shields, as part of its THRIVE@50+ campaign, to encourage people 50 and ...

Mpox transmits through close physical contact, including sexual contact. There is no evidence that it spreads easily through ...

Outbreak in several African countries has sparked the spread of disinformation online about symptoms, transmission and ...